The cost of control: Cost-effectiveness analysis of hybrid closed-loop therapy in youth

Abstract

<p> </p> <p><strong>Objective:</strong> Hybrid closed-loop (HCL) therapy is an efficacious management strategy for young people with type 1 diabetes. However, high costs prevent equitable access. We thus sought to evaluate the cost-effectiveness of HCL therapy in comparison to current care among young people with type 1 diabetes in Australia. </p> <p><strong>Methods: </strong>A patient-level Markov model was constructed to simulate disease progression for young people with type 1 diabetes using HCL therapy versus current care, with follow-up from 12 until 25 years of age. Downstream health and economic consequences were compared via decision analysis. Treatment-effects and proportions using different technologies to define ‘current care’ were based primarily on data from an Australian pediatric randomized controlled trial. Transition probabilities and utilities for health states were sourced from published studies. Costs were considered from the Australian healthcare system’s perspective. An annual discount rate of 5% was applied to future costs and outcomes. Uncertainty was evaluated with probabilistic and deterministic sensitivity analyses.</p> <p><strong>Results: </strong>Use of HCL therapy resulted in an incremental cost-effectiveness ratio (ICER) of Australian Dollars (AUD) $32,789 per quality adjusted life year (QALY) gained. The majority of simulations (93.3%) were below the commonly accepted willingness-to-pay threshold of AUD $50,000 per QALY gained in Australia. Sensitivity analyses indicated that the base-case results were robust. </p> <p><strong>Conclusions: </strong>In this first cost-effectiveness analysis of HCL technologies for the management of young people with type 1 diabetes, HCL therapy was found to be cost-effective when compared to current care in Australia.</p>